Paeoveitol D derivatives and pharmaceutical compositions thereof, and preparation methods and applications thereof
By developing paeoveitol D derivatives 1-27, the problem of the lack of lasting effects of existing melatonin receptor agonists is solved, providing effective pharmaceutical compositions for the agonistic activity of MT1 and MT2 receptors and the treatment of central nervous system diseases, Achieve a longer-lasting therapeutic effect.
Patent Information
- Application Number
- CN202111513606.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-12-10
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2041-12-10
AI Technical Summary
Existing melatonin receptor agonists are insignificant in the treatment of central nervous system diseases and have a fast metabolization, and lack of lasting derivatives.
Paeoveitol D derivatives 1-27 and preparation method are developed as novel melatonin receptor agonists, synthesized by structural modification, providing a therapeutic pharmaceutical composition for central nervous system diseases associated with melatonin receptors.
It provides agonistic activity on MT1 and MT2 receptors, extends the drug action time, improves the effect of treating central nervous system diseases, and is easy to operate and suitable for industrial production.
Smart Images

Figure CN116253704B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of pharmaceutical technology, and specifically relates to paeoveitol D derivatives 1-27 (compounds 1-27) shown in structural formula (I), pharmaceutical compositions and preparation methods thereof, and use of derivatives 1-27 or pharmaceutical compositions thereof in the preparation of melatonin receptor agonists and in drugs for treating or preventing central nervous system diseases associated with melatonin receptors. Background Art
[0002] Melatonin (MT) is an indole endogenous hormone secreted by the pineal gland. It plays an important role in regulating the circadian rhythm, immunity, aging, cardiovascular and cerebrovascular system of organisms. It mainly exerts its physiological function by activating the corresponding melatonin receptors in the body. There are three subtypes of melatonin receptors: MT 1 ,MT 2 and MT 3 , the first two are expressed in humans and other mammals. Melatonin receptors are closely related to a variety of central nervous system diseases, such as rhythm disorders, sleep disorders, depression, Alzheimer's disease, etc. Modern pharmacological studies have found that most patients with mental illness have abnormal melatonin secretion or melatonin receptor dysfunction, and the condition can be improved or alleviated by supplementing exogenous melatonin or melatonin receptor agonists. Melatonin has a wide range of effects on human physiological functions, but melatonin is not particularly effective when used directly as a medicine. When melatonin enters the human body, it is metabolized very quickly in the body, with a half-life of between 20 and 30 minutes. Therefore, the development of melatonin derivatives with longer-lasting effects has become a research hotspot today. Existing melatonin receptor agonists mainly include: 1) Simple indole type: melatonin analogs that retain the indole ring. By introducing different substituents on the indole ring, their binding force with the receptor and their activity can be changed; 2) Indole bioisostere type: mainly replacing indole with a naphthalene ring or other 6+5 system, such as indane, benzofuran, indoline and other structures; 3) Benzene derivatives: the parent nucleus only retains the benzene ring; 4) Dimer type: the molecule contains two identical or similar aromatic systems. The melatonin receptor drugs that have been marketed include: ramelteon for the treatment of insomnia with difficulty falling asleep; agomelatine for the treatment of adult depression; tasimelteon, the first drug for the treatment of non-24-hour sleep disorders in the blind.
[0003] The present invention has found that the compound paeoveitol D obtained from Sichuan red peony root has an effect on MT 1 and MT 2 The receptor has a certain agonist activity. Taking melatonin as a positive control drug, at a concentration of about 1mM, it has an effect on MT1 and MT 2 The receptor agonism rates were 57.52% and 51.67% respectively.
[0004] The present invention provides a new melatonin receptor agonist by modifying the structure of paeoveitol D to synthesize new derivatives. There is no report on paeoveitol D derivatives 1-27 in the prior art, no report on the synthesis method of compounds 1-27, no report on the preparation of melatonin receptor agonists and antidepressant activities of compounds 1-27, and no report on pharmaceutical compositions with them as active ingredients. Summary of the invention
[0005] The present invention aims to provide novel paeoveitol D derivatives 1-27 (compounds 1-27), their preparation and synthesis methods, and pharmaceutical compositions containing them as active ingredients, their use as melatonin receptor agonists, and their use in treating or preventing central nervous system diseases associated with melatonin receptors.
[0006] In order to achieve the above-mentioned object of the present invention, the present invention provides the following technical solutions:
[0007] The paeoveitol D derivative 1-27 (Compound 1-27) and its pharmaceutically acceptable salt shown in the following structural formula (I),
[0008]
[0009] Application of paeoveitol D derivatives 1-27 shown in structural formula (I) in the preparation of melatonin receptor agonists.
[0010] Use of compound 1-27 represented by structural formula (I) in the preparation of drugs for treating or improving central nervous system diseases.
[0011] The present invention also provides a pharmaceutical composition containing a therapeutically effective amount of compound 1-27 of formula (I) and a pharmaceutically acceptable carrier.
[0012] The application of the pharmaceutical composition in the preparation of a melatonin receptor agonist.
[0013] The pharmaceutical composition is used in preparing medicines for treating or preventing central nervous system diseases.
[0014] The use as described above, wherein the disease is a central nervous system disease related to melatonin receptors.
[0015] The present invention further provides a method for preparing the paeoveitol D derivatives 1-27 (compounds 1-27) of formula (I), which comprises the following steps:
[0016] Preparation of compound 1-7:
[0017] Ethyl 5-methoxy-6-methylbenzofuran-3-carboxylate is reacted with a reducing agent to obtain compound 1; compound 1 is reacted with cyclopropylcarbonyl chloride under the action of a base to obtain compound 2; compound 1 and phthalimide are reacted with triphenylphosphine and an azo reagent via a Mitsunobu reaction to obtain compound 3; compound 3 is hydrolyzed with hydrazine hydrate to obtain compound 4; compound 4 is reacted with acetyl chloride or cyclopropylcarbonyl chloride under the action of a base to obtain compounds 5-6; compound 1 is oxidized to obtain compound 7.
[0018] Preparation of compound 8-27:
[0019] Benzofuran-3-aldehyde compounds and primary or secondary amines are subjected to reductive amination in a suitable reaction solvent under the action of a suitable reducing agent to obtain compounds 8-17, 19-27, wherein the benzofuran-3-aldehyde compounds include 6-methyl-5-methoxy-3-benzofuranaldehyde or 5-methoxy-3-benzofuranaldehyde or 5-methoxy-2-methyl-3-benzofuranaldehyde or 5-methoxy-2-phenyl-3-benzofuranaldehyde, the suitable reaction solvent is dichloromethane or chloroform or methanol or ethanol, and the suitable reducing agent is sodium borohydride or sodium triacetylborohydride or sodium cyanoborohydride. Compound 17 is prepared by removing the tert-butyloxycarbonyl group under the action of a suitable acid to obtain compound 18, wherein the suitable acid is trifluoroacetic acid, p-toluenesulfonic acid, etc.
[0020] Also provided is a method for preparing the pharmaceutical composition of the present invention, which comprises the following steps: first preparing paeoveitol D derivative 1-27, and then adding a pharmaceutically acceptable carrier.
[0021] The pharmaceutical composition comprises any one or any combination of the compounds 1-27 represented by the above formula (I) and at least one pharmaceutically acceptable carrier or excipient.
[0022] The pharmaceutical composition provided by the present invention comprises at least one of the above-mentioned compounds 1-27 or any combination thereof and a pharmaceutically acceptable carrier or excipient. In the present invention, the pharmaceutically acceptable carrier or excipient is preferably a solid, semisolid or liquid diluent, a filler and a pharmaceutical product adjuvant. The present invention has no particular limitation on the pharmaceutically acceptable carrier or excipient, and any pharmaceutically acceptable carrier and / or excipient well known in the art, non-toxic and inert to humans and animals can be selected.
[0023] The present invention has no particular limitation on the method for preparing the pharmaceutical composition. At least one of compounds 1-27 can be directly mixed with a pharmaceutically acceptable carrier or excipient. The present invention has no particular limitation on the mixing process. A pharmaceutical composition can be obtained by selecting a process well known in the art.
[0024] In the present invention, when the compound 1-27 or the pharmaceutical composition is used as a melatonin receptor agonist or a drug, it can be used directly or in the form of a pharmaceutical composition, and the content of the composition in the drug is preferably 0.1-99%; in the pharmaceutical composition, the content of at least one of the compounds 1-27 in the pharmaceutical composition is preferably 0.5-90%. The pharmaceutical composition of the present invention is preferably used in the form of a dosage per unit body weight. In the present invention, the prepared drug is preferably administered in two forms: injection (intravenous injection, intramuscular injection) and oral administration.
[0025] Compared with the prior art, the present invention has the following advantages: the present invention provides a new paeoveitol D derivative, a pharmaceutical composition with the paeoveitol D derivative as an active ingredient, and also provides the use of the paeoveitol D derivative and the pharmaceutical composition thereof in the preparation of a drug for central nervous system diseases associated with melatonin receptors, provides the antidepressant activity of compound 13, and provides a method for preparing the paeoveitol D derivative. The method has readily available raw materials, is easy to operate, has a high yield, and is suitable for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 Schematic diagram of the structure of paeoveitolD derivative 1-27 (compound 1-27) of the present invention. DETAILED DESCRIPTION
[0027] In order to better understand the present invention, the essential contents of the present invention are further described below with reference to the accompanying drawings by using specific embodiments of the present invention, but the present invention is not limited thereto.
[0028] Example 1
[0029] Preparation of 5-methoxybenzofuran-3-methanol (Compound 1):
[0030]
[0031] Under nitrogen protection, ethyl 5-methoxy-6-methylbenzofuran-3-carboxylate (2.34 g, 10 mmol) was dissolved in 25 mL of dry dichloromethane, cooled to -78 °C, and a toluene solution of DIBAL-H (25 mL, 1.2 M, 30 mmol) was slowly added. After the addition was completed, the temperature was slowly raised to 0 °C and reacted for 1 h. After that, 50 mL of saturated NH 4The reaction was quenched with Cl solution, extracted with ethyl acetate (3×50 mL), the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent. The crude product was separated by silica gel column chromatography (acetone-petroleum ether, 15:85) to obtain 1.75 g of the target compound in a yield of 91%.
[0032] Structural data of compound 1:
[0033] Appearance: White solid
[0034] 1 H-NMR and 13 C-NMR data: 1 H NMR (400 MHz, CDCl 3 )δ7.50(s,1H,H-2),7.25(s,1H,H-7),7.03(s,1H,H-4),4.79(s,3H,-OMe),3.87(s,2H,H-1′),2.31(s,3H,H-2′); 13 C NMR (100 MHz, CDCl 3 )δ154.6(C-5),150.4(C-8),142.1(C-2),125.1(C-9),124.8(C-6),120. 6(C-3),113.1(C-7),99.9(C-4),56.2(C-1′),56.0(-OMe),17.2(C-2′).
[0035] High resolution mass spectrometry (ESI) calculated value C 11 H 12 O 3 Na[M+Na] + :215.0684, measured value is 215.0686.
[0036] Example 2
[0037] Preparation of compound 2:
[0038]
[0039] In a 10mL round-bottom flask, 76.9mg of compound 1 (0.4mmol) was dissolved in 3mL of dichloromethane, and DMAP (2.4mg, 0.02mmol) and 48.2μL of pyridine (0.6mmol) were added in sequence. Cyclopropylcarbonyl chloride (0.6mmol) was slowly added after cooling to 0°C in an ice-water bath, and the mixture was naturally warmed to room temperature for 5h. After the reaction was completed, 5mL of saturated sodium bicarbonate was added to quench the reaction, and the mixture was extracted with dichloromethane (3×5mL). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The crude product was separated by silica gel column chromatography (ethyl acetate-petroleum ether, 10:90) to obtain 90.5mg of the target compound with a yield of 87%.
[0040] Structural data of compound 2:
[0041] Appearance: White powder
[0042] 1 H-NMR and 13 C-NMR data: 1 H NMR (500 MHz, CDCl 3 )δ7.59(s,1H,H-2),7.27(s,1H,H-7),7.00(s,1H,H-4),5.25(s,2H,H-1′),3.89(s,3H,-OMe), 2.33(s,3H,H-2′),1.68-1.63(m,1H,H-4′),1.06-1.03(m,2H,H-5′),0.90-0.86(m,2H,H-5′); 13 C NMR (125 MHz, CDCl 3 )δ175.0(C-3′),154.7(C-5),150.2(C-8),143.8(C-2),125.1(C-9),124.8(C-6),116.2(C- 2),113.0(C-7),99.7(C-4),56.8(-OMe),55.8(C-1′),17.1(C-2′),13.0(C-4′),8.7(C-5′)
[0043] High resolution mass spectrometry (ESI) calculated value C 15 H 17 O 4 [M+H] + :261.1127, measured value is 261.2234.
[0044] Example 3
[0045] Preparation of compound 3:
[0046]
[0047] Under nitrogen protection, 0.77g alcohol (4mmol), 40mL dry tetrahydrofuran, 0.77g phthalimide (5.2mmol), 1.36g triphenylphosphine (5.2mmol) were added to a 100mL three-necked flask in sequence, and a 5mL tetrahydrofuran solution of DIAD (1.05g, 5.2mmol) was slowly added dropwise to the above solution under stirring, and the reaction was allowed to proceed overnight at room temperature. After the reaction was completed, 50mL of water was added to the reaction solution, and the mixture was extracted with ethyl acetate (3×50mL), the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent. The crude product was separated by silica gel column chromatography (ethyl acetate-petroleum ether, 25:75) to obtain 1.01g of the target compound with a yield of 79%.
[0048] Structural data of compound 3:
[0049] Appearance: White powder
[0050] 1 H-NMR and 13 C-NMR data: 1 H NMR (500 MHz, CDCl 3 )δ7.83-7.80(m,2H,H-5′),7.70(s,1H,H-2),7.69-7.65(m,2H,H-6′),7.27(s,1H ,H-7),7.20(s,1H,H-4),4.91(s,3H,-OMe),3.92(s,2H,H-1′),2.28(s,3H,H-2′); 13 C NMR (125 MHz, CDCl 3 )δ168.1(C-3′),154.6(C-5),150.0(C-8),144.5(C-2),134.1(C-6′),132.2(C-4′),124.9(C-9),124 .7(C-6),123.4(C-5′),115.9(C-3),112.9(C-7),100.2(C-4),55.9(-OMe),31.1(C-1′),17.1(C-2′).
[0051] High resolution mass spectrometry (ESI) calculated value C 19 H 16 NO 4 [M+H] + :322.1079, measured value is 322.1085
[0052] Example 4
[0053] Preparation of compound 4:
[0054]
[0055] At room temperature, 0.64 g of amide (2 mmol) was dissolved in 20 mL of methanol, and 296 μL of hydrazine hydrate (6 mmol) was added dropwise thereto under stirring, and the mixture was stirred at room temperature for 30 min, and then 5% hydrochloric acid solution (20 mL) was added and stirred overnight. After the reaction was completed, the insoluble solid was removed by filtration, 40 mL of water was added to dilute the filtrate, and the pH of the solution was adjusted to 2 with hydrochloric acid, washed with ether, the aqueous phase was collected, the pH of the solution was adjusted to 11 with potassium hydroxide, and extracted with ether (3×30 mL), the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent. The crude product was separated by silica gel column chromatography (methanol-chloroform, 10:90) to obtain 356 mg of the target compound, with a yield of 93%.
[0056] Appearance: Light yellow solid
[0057] 1 H-NMR and 13 C-NMR data: 1 H NMR (500 MHz, CDCl 3 )δ7.46(s,1H,H-2),7.23(s,1H,H-7),6.95(s,1H,H-4),3.96(s,2H,H-1′),3.87(s,3H,-OMe),2.53(brs,2H,-NH 2 ),2.30(s,3H,H-2′); 13 C NMR (125 MHz, CDCl 3 )δ154.5(C-5),150.3(C-8),141.4(C-2),124.9(C-9),124.8(C-6),121. 6(C-3),113.1(C-7),99.6(C-4),56.0(-OMe),36.1(C-1′),17.2(C-2′).
[0058] High resolution mass spectrometry (ESI) calculated value C 11 H 13 NO 2 Na[M+Na] + :214.0844, measured value is 214.0853.
[0059] Example 5
[0060] Preparation of compound 5:
[0061]
[0062] In a 10mL round-bottom flask, 28.7mg of primary amine (0.15mmol) was dissolved in 1mL of dry dichloromethane, and then 31μL of triethylamine (2.25mmol) was added. After the reaction solution was cooled to 0℃, acetyl chloride (11.7μL, 0.165mmol) was added thereto. The reaction was continued at 0℃ for 30min and then warmed to room temperature for overnight reaction. The solvent was removed by concentration under reduced pressure, and the crude product was separated by silica gel column chromatography (ethyl acetate-petroleum ether, 20:80) to obtain 34mg of the target compound with a yield of 96%.
[0063] Appearance: White powder
[0064] 1 H-NMR and 13 C-NMR data: 1 H NMR (500 MHz, CDCl 3 )δ7.45(s,1H,H-2),7.23(s,1H,H-7),6.96(s,1H,H-4),5.81(brs,1H,NH),4.49 (d,J=5.5Hz,2H,H-1′),3.85(s,3H,-OMe),2.30(s,3H,H-2′),1.99(s,3H,H-4′); 13 C NMR (125 MHz, CDCl 3 )δ170.2(C-3′),154.6(C-5),150.2(C-8),142.4(C-2),125.2(C-9),124.7(C-6),117 .8(C-3),113.1(C-7),99.8(C-4),55.9(-OMe),33.5(C-1′),23.3(C-4′),17.2(C-2′).
[0065] High resolution mass spectrometry (ESI) calculated value C 13 H 15 NO 3 Na[M+Na] + :256.0950, the measured value is 256.0971.
[0066] Example 6
[0067] Preparation of compound 6:
[0068]
[0069] Except that acetyl chloride was replaced by cyclopropylcarbonyl chloride, the other required raw materials, reagents and preparation method were the same as those in Example 5, to obtain 36 mg of the target compound with a yield of 94%.
[0070] Appearance: White powder
[0071] 1 H-NMR and 13 C-NMR data: 1 H NMR (500 MHz, CDCl 3 )δ7.47(s,1H,H-2),7.25(s,1H,H-7),6.97(s,1H,H-4),4.55(d,J=5.5Hz,2H,H-1′),3.86(s,3H,-O Me),2.31(s,3H,H-2′),1.35-1.30(m,1H,H-4′),1.04-1.01(m,2H,H-5′),0.76-0.74(m,2H,H-5′); 13 C NMR (125 MHz, CDCl 3 )δ173.7(C-3′),154.6(C-5),150.3(C-8),142.3(C-2),125.1(C-9),124.8(C-6),118.1(C-3 ),113.1(C-7),100.0(C-4),55.9(-OMe),33.7(C-1′),17.2(C-2′),14.7(C-4′),7.4(C-5′).
[0072] High resolution mass spectrometry (ESI) calculated value C 15 H 18 NO 3 [M+H] + :260.1287, measured value is 260.1295.
[0073] Example 7
[0074] Preparation of compound 7:
[0075]
[0076] At room temperature, 0.96 g of alcohol (5 mmol) was dissolved in 10 mL of dichloromethane, and 3.18 g of Dess-Martin reagent (7.5 mmol) was added thereto under stirring, and the reaction was carried out at room temperature for 2 h. After the reaction was completed, 20 mL of dichloromethane was added to dilute the reaction solution, and the solution was washed with saturated sodium thiosulfate (20 mL), saturated sodium bicarbonate (20 mL) and saturated brine in sequence, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent. The crude product was separated by silica gel column chromatography (ethyl acetate-petroleum ether, 10:90) to obtain 0.85 g of the target compound, with a yield of 89%.
[0077] Appearance: Light yellow solid
[0078] 1 H-NMR and 13C-NMR data: 1 H NMR (500 MHz, CDCl 3 )δ10.11(s,1H,-CHO),8.16(s,1H,H-2),7.53(s,1H,H-7),7.30(s,1H,H-4),3.90(s,3H,-OMe),2.32(s,3H,H-2′); 13 C NMR (125 MHz, CDCl 3 )δ185.2(C-1′),156.0(C-5),155.3(C-6),150.7(C-8),126.9(C-1),124 .1(C-8),121.1(C-6),113.0(C-7),102.0(C-4),56.0(OMe),17.3(C-2′).
[0079] High resolution mass spectrometry (ESI) calculated value C 11 H 10 O 3 Na[M+Na] + :213.0528, measured value is 213.0536.
[0080] Example 8
[0081] Preparation of compound 8:
[0082]
[0083] Under nitrogen protection, compound 7 (57.1 mg, 0.3 mmol) was dissolved in 4 mL of dichloromethane. Under stirring, 0.45 mmol of dimethylamine, 95.4 mg of sodium triacetylborohydride (0.45 mmol) and 3.4 μL of acetic acid (0.06 mmol) were added in sequence. The mixture was reacted at room temperature for 24 h. After the reaction was completed, 1 M sodium hydroxide solution (5 mL) was added to quench the reaction. The mixture was extracted with ethyl acetate (3×10 mL). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent. The crude product was separated by silica gel column chromatography (ethyl acetate-petroleum ether, 20:80) to obtain 48 mg of the target compound in a yield of 73%.
[0084] Appearance: White powder
[0085] 1 H-NMR and 13 C-NMR data: 1 H NMR (500 MHz, CDCl 3)δ7.47(s,1H,H-2),7.24(s,1H,H-7),7.04(s,1H,H-4),3.89(s,3H,-OMe),3.56(s,2H,H-1′),2.31(overlap,9H,H-2′,-NMe 2 ); 13 CNMR (125MHz, CDCl 3 )δ154.5(C-5),150.2(C-8),143.1(C-2),126.0(C-9),124.7(C-6),117.4(C-1),112.9(C-7),100.3(C-4),56.0(OMe),53.2(C-1′),45.4(-NMe 2 ),17.2(C-2′).
[0086] High resolution mass spectrometry (ESI) calculated value C 13 H 18 NO 2 [M+H] + :220.1332, the measured value is 220.1324.
[0087] Example 9
[0088] Preparation of compound 9:
[0089]
[0090] Except that dimethylamine was replaced by diethylamine, the other required raw materials, reagents and preparation method were the same as those in Example 8, and 60 mg of the target compound was obtained with a yield of 81%.
[0091] Appearance: White powder
[0092] 1 H-NMR and 13 C-NMR data: 1 H NMR (500 MHz, CDCl 3 )δ7.44(s,1H,H-2),7.24(s,1H,H-7),7.10(s,1H,H-4),3.88(s,3H,-OMe),3.68(s,2 H,H-1′),2.56(q,J=7.0Hz,4H,H-3′),2.32(s,3H,H-2′),1.09(t,J=7.0Hz,6H,H-4′); 13 C NMR (125 MHz, CDCl 3): δ154.2(C-5),150.2(C-8),142.6(C-2),126.4(C-9),124.4(C-6),118.4(C-1),112 .8(C-7),100.7(C-4),55.9(OMe),47.0(C-1′),46.9(C-3′),17.1(C-2′),12.2(C-4′).
[0093] High resolution mass spectrometry (ESI) calculated value C 15 H 22 NO 2 [M+H] + :248.1645, the measured value is 248.1640.
[0094] Example 10
[0095] Preparation of compound 10:
[0096]
[0097] Except that dimethylamine was replaced by dipropylamine, the other required raw materials, reagents and preparation method were the same as those in Example 8, and 63 mg of the target compound was obtained with a yield of 77%.
[0098] Appearance: White powder
[0099] 1 H-NMR and 13 C-NMR data: 1 H NMR (500 MHz, CDCl 3 )δ7.42(s,1H,H-2),7.23(s,1H,H-7),7.13(s,1H,H-4),3.87(s,3H,OMe),3.64(s,2H,H-1′),2.4 1(t,J=7.5Hz,4H,H-4′),2.32(s,3H,H-2′),1.56-1.49(m,4H,H-4′),0.88(t,J=7.5Hz,6H,H-5′); 13 C NMR (125 MHz, CDCl 3 )δ154.2(C-5),150.3(C-8),142.5(C-2),126.4(C-9),124.3(C-6),118.8(C-1),112.7(C-7 ),101.0(C-4),56.0(C-3′),55.9(OMe),48.5(C-1′),20.5(C-4′),17.2(C-2′),12.1(C-5′).
[0100] High resolution mass spectrometry (ESI) calculated value C17 H 26 NO 2 [M+H] + :276.1964, measured value is 276.1955.
[0101] Embodiment 11
[0102] Preparation of compound 11:
[0103]
[0104] Except that dimethylamine was replaced by dibutylamine, the other required raw materials, reagents and preparation method were the same as those in Example 8, and 64 mg of the target compound was obtained with a yield of 70%.
[0105] Appearance: White powder
[0106] 1 H-NMR and 13 C-NMR data: 1 H NMR (500 MHz, CDCl 3 )δ7.41(s,1H,H-2),7.22(s,1H,H-7),7.11(s,1H,H-4),3.86(s,3H,OMe),3.64(s,2H,H-1′),2.44(t,J=7.5Hz ,4H,H-3′),2.32(s,3H,H-2′),1.51-1.46(m,4H,H-4′),1.35-1.28(m,4H,H-5′),0.88(t,J=7.5Hz,6H,H-6′); 13 C NMR (125 MHz, CDCl 3 )δ154.2(C-5),150.3(C-8),142.5(C-2),126.4(C-9),124.3(C-2),118.4(C-1),112.7(C-7),101. 0(C-4),55.8(OMe),53.7(C-3′),48.4(C-1′),29.5(C-4′),20.8(C-5′),17.2(C-2′),14.2(C-6′).
[0107] High resolution mass spectrometry (ESI) calculated value C 19 H 31 NO 2 [M+H] + :304.2271, measured value is 304.2262.
[0108] Example 12
[0109] Preparation of compound 12:
[0110]
[0111] Except that dimethylamine was replaced by N-methylhomopiperazine, the other required raw materials, reagents and preparation method were the same as those in Example 8, and 73 mg of the target compound 12 was obtained with a yield of 85%.
[0112] Compound 12
[0113] Appearance: Light yellow viscous liquid
[0114] 1 H-NMR and 13 C-NMR data: 1 H NMR (500 MHz, CDCl 3 )δ7.42(s,1H,H-2),7.22(s,1H,H-7),7.13(s,1H,H-4),3.88(s,3H,OMe),3.70(s,2H,H-1′),2.76(t,J=6.0Hz,2H,H-3′),2.75-2.73(m ,2H,H-3′,H-7′),2.69(t,J=6.0Hz,2H,H-5′),2.63-2.61(m,2H,H-6′),2.36(s,3H,H-8′),2.31(s,3H,H-2′),1.86-1.82(m,2H,H-4′); 13 C NMR (125 MHz, CDCl 3 )δ154.2(C-5),150.3(C-8),142.5(C-2),126.1(C-9),124.5(C-6),118.6(C-1),112.8(C-7),100.9(C-4),58.6 (C-6′),56.5(C-7′),55.9(OMe),54.4(C-5′),54.2(C-3′),52.6(C-1′),47.0(C-8′),27.4(C-4′),17.1(C-2′).
[0115] High resolution mass spectrometry (ESI) calculated value C 17 H 25 N 2 O 2 [M+H] + :289.1911, measured value is 289.1909.
[0116] Embodiment 13
[0117] Preparation of compound 13:
[0118]
[0119] Except that dimethylamine was replaced by N-methylpiperazine, the other required raw materials, reagents and preparation method were the same as those in Example 8, to obtain 66 mg of the target compound 13 with a yield of 81%.
[0120] Appearance: Light yellow powder
[0121] 1 H-NMR and 13 C-NMR data: 1 H NMR (500 MHz, CDCl 3 )δ7.43(s,1H,H-2),7.22(s,1H,H-7),7.08(s,1H,H-4),3.87(s,3H,OMe),3.60-3.59(m,2H,H -1′),2.57-2.40(m,8H,H-3′,H-4′),2.30(s,3H,H-2′),2.30(s,3H,H-2′),2.27(s,3H,H-5′); 13 C NMR (125 MHz, CDCl 3 )δ154.3(C-5),150.1(C-8),142.8(C-1),126.1(C-9),124.5(C-6),117.2(C-1),112.8(C-7 ),100.6(C-4),55.9(OMe),55.3(C-4′),53.1(C-3′),52.2(C-1′),46.1(C-5′),17.1(C-2′).
[0122] High resolution mass spectrometry (ESI) calculated value C 16 H 23 N 2 O 2 [M+H] + :275.1754, the measured value is 275.1745.
[0123] Embodiment 14
[0124] Preparation of compound 14:
[0125]
[0126] Except that dimethylamine was replaced by N-ethylpiperazine, the other required raw materials, reagents and preparation method were the same as those in Example 8, to obtain 63 mg of the target compound 14 with a yield of 73%.
[0127] Appearance: Light yellow powder
[0128] 1 H-NMR and 13 C-NMR data: 1H NMR (500 MHz, CDCl 3 )δ7.44(s,1H,H-2),7.22(s,1H,H-7),7.09(s,1H,H-4),3.87(s,3H,OMe),3.61(s,2H,H-1′),2.59-2 .26(m,8H,H-3′,H-4′),2.39(q,J=7.2Hz,2H,H-5′),2.30(s,3H,H-2′),1.07(t,J=7.0Hz,1H,H-6′); 13 C NMR (125 MHz, CDCl 3 )δ154.3(C-5),150.2(C-8),142.8(C-2),126.2(C-9),124.5(C-6),117.3(C-1),112.8(C-7),100. 7(C-4),55.9(OMe),53.2(C-4′),53.1(C-3′),52.4(C-1′),52.2(C-5′),17.1(C-2′),12.1(C-6′).
[0129] High resolution mass spectrometry (ESI) calculated value C 17 H 26 N 2 O 2 [M+H] + :289.1911, the measured value is 289.1901.
[0130] Embodiment 15
[0131] Preparation of compound 15:
[0132]
[0133] Except that dimethylamine was replaced by 1-(2-pyrazine)piperazine, the other required raw materials, reagents and preparation methods were the same as those in Example 8 to obtain 68 mg of the target compound 15 with a yield of 67%.
[0134] Appearance: Light yellow powder
[0135] 1 H-NMR and 13 C-NMR data: 1 H NMR (500 MHz, CDCl 3)δ8.11(d,J=1.5Hz,1H,H-6′),8.05-8.04(m,1H,H-7′),7.83(d,J=2.5Hz,1H,H-8′),7.46(s,1H,H-2),7.25(s,1H,H-7),7.12 (s,1H,H-4),3.87(s,3H,OMe),3.66(s,2H,H-1′),3.60(t,J=5.5Hz,4H,H-4′),2.61(t,J=5.0Hz,4H,H-3′),2.32(s,3H,H-2′); 13 C NMR (125 MHz, CDCl 3 )δ155.1(C-5′),154.4(C-5),150.3(C-8),142.9(C-2),141.8(C-8′),133.0(C-7′),131.1(C-6′),125.9(C-9),12 4.7(C-6),116.9(C-3),112.9(C-7),100.6(C-4),55.9(OMe),52.7(C-3′),52.4(C-1′),44.7(C-4′),17.1(C-2′).
[0136] High resolution mass spectrometry (ESI) calculated value C 19 H 23 N 4 O 2 [M+H] + :339.1816, measured value is 339.1793.
[0137] Example 16
[0138] Preparation of compound 16:
[0139]
[0140] Except that dimethylamine was replaced by acetylpiperazine, the other required raw materials, reagents and preparation method were the same as those in Example 8, and 67 mg of the target compound 16 was obtained, with a yield of 74%.
[0141] Appearance: Light yellow powder
[0142] 1 H-NMR and 13 C-NMR data: 1 H NMR (500 MHz, CDCl 3)δ7.41(s,1H,H-3),7.22(s,1H,H-7),7.06(s,1H,H-4),3.85(s,3H,OMe),3.61(t,J=5.0Hz,2H,H-4′),3.59(s ,2H,H-1′),3.42(t,J=5.0Hz,2H,H-6′),2.46-2.43(m,4H,H-3′,H-5′),2.29(s,3H,H-2′),2.05(s,3H,H-8′); 13 C NMR (125 MHz, CDCl 3 )δ168.9(C-8′),154.3(C-5),150.1(C-8),142.8(C-2),125.8(C-9),124.7(C-6),116.8(C-3),112.8(C-7),100 .4(C-4),55.8(OMe),52.9(C-3′),52.8(C-5′),52.1(C-1′),46.4(C-4′),41.5(C-6′),21.3(C-8′),17.0(C-2′).
[0143] High resolution mass spectrometry (ESI) calculated value C 17 H 23 N 2 O 3 [M+H] + :303.1703, measured value is 303.1689.
[0144] Embodiment 17
[0145] Preparation of compound 17:
[0146]
[0147] Except that dimethylamine was replaced by 1-Boc-piperazine, the other required raw materials, reagents and preparation methods were the same as those in Example 8 to obtain 63 mg of the target compound 17 with a yield of 58%.
[0148] Appearance: Light yellow powder
[0149] 1 H-NMR and 13 C-NMR data: 1 H NMR (500 MHz, CDCl 3)δ7.43(s,1H,H-2),7.24(s,1H,H-7),7.09(s,1H,H-4),3.88(s,3H,OMe),3.61(s,2H,H-1′),3 .43(d,J=5.0Hz,4H,H-4′),2.44(d,J=5.0Hz,4H,H-3′),2.31(s,3H,H-2′),1.45(s,9H,H-7′); 13 C NMR (125 MHz, CDCl 3 )δ154.9(C-5′),154.4(C-5),150.3(C-8),142.9(C-2),126.0(C-9),124.7(C-6),117.1(C-1),112.9(C-7 ),100.7(C-4),79.7(C-6′),56.0(OMe),53.0(C-3′),53.0(C-4′),52.4(C-1′),28.6(C-7′),17.2(C-2′).
[0150] Embodiment 18
[0151] Preparation of compound 18:
[0152]
[0153] 36 mg of compound 17 (0.1 mmol) was dissolved in 3 mL of dichloromethane, and 0.2 mL of trifluoroacetic acid was added thereto with stirring. After reacting at room temperature for 6 h, 10 mL of saturated sodium bicarbonate solution was added to quench the reaction. The mixture was extracted with dichloromethane (3×5 mL). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent. The crude product was separated by silica gel column chromatography (methanol-chloroform, 5:95) to obtain 25 mg of the target compound in a yield of 98%.
[0154] Appearance: Light yellow powder
[0155] 1 H-NMR and 13 C-NMR data: 1 H NMR (500MHz, CD 3 OD)δ7.55(s,1H,H-2),7.19(s,1H,H-7),7.13(s,1H,H-4),3.85(s,3H,OMe),3.61 (s,2H,H-1′),2.88(t,J=5.0Hz,4H,H-4′)2.52(brs,4H,H-3′),2.25(s,3H,H-2′); 13 C NMR (125MHz, CD 3OD)δ155.8(C-5),151.5(C-9),144.9(C-2),127.3(C-8),125.6(C-6),117.4(C-3),113 .5(C-7),101.3(C-4),56.2(OMe),53.9(C-3′),52.8(C-1′),46.0(C-4′),17.1(C-2′).
[0156] High resolution mass spectrometry (ESI) calculated value C 15 H 21 N 2 O 2 [M+H] + :261.1598, measured value is 261.1605.
[0157] Embodiment 19
[0158] Preparation of compound 19:
[0159]
[0160] Except that dimethylamine was replaced with tetrahydropyrrole, the remaining raw materials, reagents and preparation method were the same as in Example 8 to obtain 55 mg of the target compound 19 with a yield of 75%.
[0161] Appearance: Light yellow oil
[0162] 1 H-NMR and 13 C-NMR data: 1 H NMR (500 MHz, CDCl 3 )δ7.49(s,1H,H-2),7.24(s,1H,H-7),7.05(s,1H,H-4),3.88(s,3H,OMe),3.77(s ,2H,H-1′),2.65-2.62(m,4H,H-3′),2.31(s,3H,H-2′),1.83-1.80(m,4H,H-4′); 13 C NMR (125 MHz, CDCl 3 )δ154.5(C-5),150.1(C-8),142.9(C-2),126.0(C-9),124.6(C-2),117.7(C-1),112. 9(C-7),100.3(C-4),56.0(OMe),54.2(C-3′),49.1(C-1′),23.7(C-4′),17.1(C-2′).
[0163] High resolution mass spectrometry (ESI) calculated value C 15 H 20NO 2 [M+H] + :246.1489, measured value is 246.1480.
[0164] Embodiment 20
[0165] Preparation of compound 20:
[0166]
[0167] Except that compound 7 was replaced by 5-methoxy-3-benzofuranaldehyde and dimethylamine was replaced by tetrahydropyrrole, the other required raw materials, reagents and preparation method were the same as those in Example 8, and 54 mg of the target compound 20 was obtained with a yield of 79%.
[0168] Appearance: Light yellow oil
[0169] 1 H-NMR and 13 C-NMR data: 1 H NMR (400 MHz, CDCl 3 )δ7.50(s,1H,H-2),7.28(d,J=8.8Hz,1H,H-7),7.05(d,J=2.4Hz,1H,H-4),6.82(dd,J=8.8,2.4Hz, 1H,H-6),3.78(s,3H,OMe),3.72(s,2H,H-1′),2.59(t,J=6.0Hz,4H,H-2′),1.76-1.73(m,4H,H-3′); 13 C NMR (100 MHz, CDCl 3 )δ156.0(C-5),150.4(C-8),144.3(C-2),128.6(C-9),117.3(C-3),113.1(C-6 ),112.0(C-7),102.7(C-4),56.1(OMe),53.9(C-2′),48.7(C-1′),23.6(C-3′).
[0170] High resolution mass spectrometry (ESI) calculated value C 14 H 18 NO 2 C[M+H] + :232.1332, the measured value is 232.1316.
[0171] Embodiment 21
[0172] Preparation of compound 21:
[0173]
[0174] Except that dimethylamine was replaced by morpholine, the other required raw materials, reagents and preparation method were the same as those in Example 8 to obtain 69 mg of the target compound 21 with a yield of 88%.
[0175] Appearance: Light yellow oil
[0176] 1 H-NMR and 13 C-NMR data: 1 H NMR (500 MHz, CDCl 3 )δ7.45(s,1H,H-2),7.25(s,1H,H-7),7.12(s,1H,H-4),3.89(s,3H,-OMe),3.72(t,J =5.0Hz,4H,H-4′),3.60(s,2H,H-1′),2.50(t,J=4.5Hz,4H,H-3′),2.34(s,3H,H-2′); 13 C NMR (125 MHz, CDCl 3 )δ154.3(C-5),150.2(C-8),142.8(C-2),126.0(C-9),124.7(C-6),116.9(C-1),112. 8(C-7),100.6(C-4),67.2(C-4′),55.9(OMe),53.7(C-3′),52.7(C-1′),17.1(C-2′).
[0177] High resolution mass spectrometry (ESI) calculated value C 15 H 20 NO 3 [M+H] + :262.1438, the measured value is 262.1436.
[0178] Embodiment 22
[0179] Preparation of compound 22:
[0180]
[0181] Except that compound 7 was replaced by 5-methoxy-3-benzofuranaldehyde and dimethylamine was replaced by morpholine, the other required raw materials, reagents and preparation method were the same as those in Example 8, to obtain 67 mg of the target compound 22 with a yield of 90%.
[0182] Appearance: Light yellow oily powder
[0183] 1 H-NMR and 13 C-NMR data: 1 H NMR (400 MHz, CDCl3 )δ7.40(s,1H,H-2),7.24(d,J=8.8Hz,1H,H-7),7.09(d,J=2.4Hz,1H,H-4),6.80(dd,J=8.8,2.4Hz,1H ,H-6),3.75(s,3H,OMe),3.60(t,J=4.4Hz,4H,H-3′),3.48(s,2H,H-1′),2.38(t,J=4.4Hz,4H,H-3′); 13 C NMR (125 MHz, CDCl 3 )δ155.8(C-5),150.5(C-8),144.0(C-2),128.5(C-9),116.9(C-3),112.9(C-6 ),111.8(C-7),103.2(C-4),67.1(C-3′),55.9(OMe),53.6(C-2′),52.5(C-1′).
[0184] High resolution mass spectrometry (ESI) calculated value C 14 H 18 NO 3 [M+H] + :248.1281, measured value is 248.1277.
[0185] Embodiment 23
[0186] Preparation of compound 23:
[0187]
[0188] Except that compound 7 was replaced by 5-methoxy-3-benzofuranaldehyde and dimethylamine was replaced by N-methylpiperazine, the remaining raw materials, reagents and preparation method were the same as those in Example 8, to obtain 67 mg of the target compound 22 with a yield of 86%.
[0189] Appearance: Light yellow powder
[0190] 1 H-NMR and 13 C-NMR data: 1 H NMR (400 MHz, CDCl 3 )δ7.50(s,1H,H-2),7.32(d,J=8.8Hz,1H,H-7),7.09(d,J=2.4Hz,1H,H-4),6.86(dd,J=8.8,2.4Hz ,1H,H-5),3.82(s,3H,OMe),3.64(s,2H,H-1′),2.85-2.73(m,8H,H-2′,H-3′),2.51(s,3H,H-4′);13 C NMR (100 MHz, CDCl 3 )155.9(C-5),150.5(C-8),144.5(C-2),128.3(C-9),116.2(C-1),113.0(C-6),112. 0(C-7),103.1(C-4),56.1(OMe),54.0(C-3′),51.4(C-1′),50.7(C-2′),44.2(C-4′).
[0191] High resolution mass spectrometry (ESI) calculated value C 15 H 21 N 2 O 2 [M+H] + :261.1598, the measured value is 261.1598.
[0192] Embodiment 24
[0193] Preparation of compound 24:
[0194]
[0195] Except that compound 7 was replaced by 2-methyl-5-methoxy-3-benzofuranaldehyde and dimethylamine was replaced by N-methylpiperazine, the remaining raw materials, reagents and preparation method were the same as those in Example 8, to obtain 47 mg of the target compound 24 with a yield of 57%.
[0196] Appearance: Light yellow powder
[0197] 1 H-NMR and 13 C-NMR data: 1 H NMR (400 MHz, CDCl 3 )δ7.26-7.24(m,1H,H-7),7.12-7.11(m,1H,H-4),6.81-6.78(m,1H,H-6),3.84(s,3H,OMe ),3.53(s,2H,H-1′),2.55-2.45(m,8H,H-3′,H-4′),2.40(s,3H,H-5′),2.28(s,3H,H-2′); 13 C NMR (100 MHz, CDCl 3)δ155.7(C-5),153.8(C-2),149.0(C-8),130.5(C-9),111.5(C-1),111.2(C-6),110.8(C-7 ),103.2(C-4),56.1(OMe),55.4(C-4′),53.1(C-3′),52.2(C-1′),46.1(C-5′),12.5(C-2′).
[0198] Embodiment 25
[0199] Preparation of compound 25:
[0200]
[0201] Except that compound 7 was replaced by 2-methyl-5-methoxy-3-benzofuranaldehyde and dimethylamine was replaced by N-methylpiperazine, the remaining raw materials, reagents and preparation method were the same as those in Example 8 to obtain 45 mg of the target compound 25 with a yield of 45%.
[0202] Appearance: Light yellow powder
[0203] 1 H-NMR and 13 C-NMR data: 1 H NMR (400 MHz, CDCl 3 )δ7.88(d,J=7.2Hz,2H,H-6′),7.41-7.37(m,2H,H-7′),7.32-7.28(m,2H,H-7,H-8′),7.14(d,J=2.8Hz,1H,H-4),6.8 3(dd,J=8.8,2.8Hz,1H,H-6),3.80(s,3H,OMe),3.63(s,2H,H-1′),2.55-2.38(m,8H,H-2′,H-3′),2.22(s,3H,H-4′); 13 C NMR (100 MHz, CDCl 3 )δ155.9(C-2),154.3(C-5),148.9(C-8),131.5(C-5′),131.1(C-8),128.7(C-7′),128.5(C-8′),127.7(C-5′),11 3.0(C-3),112.9(C-6),111.5(C-7),103.0(C-4),56.0(OMe),55.4(C-3′),53.1(C-2′),52.3(C-4′),46.1(C-1′).
[0204] High resolution mass spectrometry (ESI) calculated value C 21 H25 N 2 O 2 [M+H] + :337.1911, measured value is 337.1896.
[0205] Embodiment 26
[0206] Preparation of compound 26:
[0207]
[0208] Except that dimethylamine was replaced by piperazine, the other required raw materials, reagents and preparation method were the same as those in Example 8, to obtain 41 mg of the target compound 26 with a yield of 63%.
[0209] Appearance: Light yellow powder
[0210] 1 H-NMR and 13 C-NMR data: 1 H NMR (500 MHz, CDCl 3 )δ7.44(s,2H,H-2),7.23(s,2H,H-7),7.08(s,2H,H-4),3.87(s,6H,OMe),3.62(s,4H,H-1′),2.58(brs,8H,H-3′),2.31(s,6H,H-2′); 13 C NMR (125 MHz, CDCl 3 )δ154.3(C-5),150.2(C-8),142.8(C-2),126.2(C-9),124.6(C-2),117.3(C-1 ),112.8(C-7),100.7(C-4),56.0(OMe),53.3(C-1′),52.2(C-3′),17.1(C-2′).
[0211] High resolution mass spectrometry (ESI) calculated value C 26 H 30 N 2 O 4 [M+H] + :435.2278, the measured value is 435.2238.
[0212] Embodiment 27
[0213] Preparation of compound 27:
[0214]
[0215] Except that dimethylamine was replaced by piperazine, the other required raw materials, reagents and preparation method were the same as those in Example 8, to obtain 31 mg of the target compound 26 with a yield of 46%.
[0216] Appearance: Light yellow powder
[0217] 1 H-NMR and 13 C-NMR data: 1 H NMR (500 MHz, CDCl 3 )δ7.42(s,2H,H-2),7.23(s,2H,H-7),7.10(s,2H,H-4),3.83(s,6H,OMe),3.74(s,4H,H-1′) ,2.80(t,J=6.0Hz,4H,H-3′),2.74(s,4H,H-5′),2.32(s,6H,H-2′),1.88-1.84(m,2H,H-4′); 13 C NMR (125 MHz, CDCl 3 )δ154.3(C-5),150.3(C-8),142.6(C-2),126.1(C-9),124.6(C-6),118.2(C-1),112.8(C-7 ),100.9(C-4),55.9(OMe),55.4(C-5′),54.1(C-3′),52.4(C-1′),27.8(C-4′),17.2(C-2′).
[0218] High resolution mass spectrometry (ESI) calculated value C 27 H 33 N 2 O 4 [M+H] + :449.2435, measured value is 449.2411.
[0219] Embodiment 28
[0220] The paeoveitol D derivative provided by the present invention has an effect on MT 1 and MT 2 Receptor agonist activity.
[0221] 1 Materials and Methods
[0222] 1.1 Materials
[0223] Melatonin receptor MT 1 and MT 2 The cell lines used in the agonist activity screening correspond to human renal epithelial cells HEK293-MT 1 and HEK293-MT 2; Cell culture medium (Dulbecco's Modified Eage Medium, DMEM) containing 10% fetal bovine serum; No-wash calcium flux kit.
[0224] 1.2 Instruments
[0225] CO 2 Constant temperature incubator Thermo Forma 3310 (USA); inverted biological microscope XD-101 (Nanjing); Flexstation 3 Benchtop Multi-Mode Microplate Reader (Molecular Devices, Sunnyvale, California, USA).
[0226] 1.3 Experimental process
[0227] A 96-well black-walled transparent-bottom cell culture plate was coated with BD Matrigel matrix and incubated at 37°C for 1 h. The supernatant was aspirated and the corresponding HEK293 cells were seeded in the 96-well black-walled transparent-bottom cell culture plate at a density of 4 × 10 cells per well and incubated at 37°C for 1 h. 2 Culture in a 37°C constant temperature incubator with a concentration of 5% for 16 to 24 hours; discard the original culture medium, add 100 μL / well of freshly prepared dye solution, and incubate at 37°C in the dark for 60 minutes. Preparation of test samples: Prepare test samples of different concentrations. Add a specific volume of the test sample to the cells, with the sample volume added being 50 μL / well, and use the Flexstation 3 multifunctional microplate reader to determine the agonist effect of the sample crystal on the melatonin receptor. Use Graphpad prism 5 software to analyze the experimental results.
[0228] 2 Results
[0229] Compounds 7, 17 and 25 had no significant effects on MT at a tested concentration of 1.0 mM. 1 The receptor has a certain agonist activity; compounds 11, 16, 21 and 22 have a certain agonist activity on MT 1 The receptors have good agonist effects. Compounds 1, 15 and 27 have good agonist effects on MT 1 The receptors have good agonist effects. Compounds 4, 8-10, 12-14, 18-19, 23 and 26 have good agonist effects on MT 1 It has strong stimulatory activity, and the stimulatory rate is significantly higher than that of paeoveitol D.
[0230] Compounds 7 and 16 have an effect on MT 2 The receptor has a certain agonist activity; compounds 10, 17, 22 and 25 have a certain agonist activity on MT 2The receptors showed comparable agonist effects to paeoveitol D. Compounds 15, 21, 23, and 27 had an agonist effect on MT 2 The receptor has a good agonist effect, and the agonist activity is stronger than paeoveitol D. Compounds 1, 4, 8-9, 12-14, 18-20 and 26 have a good agonist effect on MT 2 It has strong stimulatory activity, and the stimulatory rate is significantly higher than that of paeoveitol D.
[0231] Compounds 4, 8-10, 18-19 and 26 have an effect on MT 1 and MT 2 The receptors all had significant effects, and the excitation rate was 2-3 times that of the original compound (see Table 1).
[0232] 3 Conclusion
[0233] The experimental results showed that compounds 1, 15 and 27 had an effect on MT 1 The receptors have good agonist effects. Compounds 4, 8-10, 12-14, 18-19, 23 and 26 have good agonist effects on MT 1 Compounds 15, 21, 23 and 27 have strong agonist activity against MT 2 The receptors have good agonist effects. Compounds 1, 4, 8-9, 12-14, 18-20 and 26 have good agonist effects on MT 2 The above results indicate that these compounds can be used as novel melatonin receptor agonists and can treat or improve central nervous system diseases related to melatonin receptors.
[0234] Table 1 Effects of Compounds 1-27 on MT 1 and MT 2 Receptor agonism
[0235]
[0236] Note: Agomelatine was used as a positive control, the maximum agonist rate of melatonin (MT) was set as 100%, and the test concentration of the compound was 1.0 mM.
[0237] Embodiment 29:
[0238] Effect of compound 13 on the immobility time in the forced swimming test in mice.
[0239] 1 Materials and Methods
[0240] Drugs and reagents
[0241] Sodium carboxymethylcellulose (CMCNa) and positive drug fluoxetine were purchased from Sane Chemical Technology (Shanghai) Co., Ltd. The test drug (Compound 13) was prepared from Example 13
[0242] Experimental instruments
[0243] XQT mouse forced swimming hardware from Xuzhou Bona Information Technology Co., Ltd. and Any-Maze animal behavior recording and tracking software from the United States.
[0244] Experimental animals
[0245] Kunming mice, SPF grade, weighing 18-20g, were purchased from Beijing Huafukang Biotechnology Co., Ltd. Animal Certificate No.: SCXK (Beijing) 2014-0004. Mice were group-housed 6 per cage, with free access to food and water, room temperature 21±1℃, 12h light / 12h dark per day, and the experiment began after the animals had adapted to the new breeding environment for 7 days. They were fasted for 12h before the experiment and had free access to water.
[0246] 2 Experimental Procedure
[0247] Mice were randomly divided into 7 groups according to their weight balance, including blank control group (0.5% CMCNa), fluoxetine positive control group (20 mg / kg), compound 13 dose group 1 (10 mg / kg), compound 12 dose group 2 (20 mg / kg), compound 13 dose group 3 (40 mg / kg), compound 13 dose group 4 (80 mg / kg), and compound 13 dose group 5 (160 mg / kg), with 12 mice in each group. Forced swimming test was performed 24h and 1h after oral administration before the test. Mice were placed in a glass container with a diameter of 15 cm, a height of 25 cm, and a water depth of 10 cm. The water temperature was 25±1°C. The movement of mice was recorded by video camera for 6 minutes. The immobility time of mice within 4 minutes was counted using Any-Maze behavior tracking software as an indicator of antidepressant activity.
[0248] 3 Results
[0249] After 2 days of administration, 20, 40, 80 and 160 mg / kg of compound 13 and fluoxetine (20 mg / kg) could significantly shorten the immobility time of mice forced swimming (P<0.05 or P<0.01), while the low-dose group only showed a shortening trend without statistical difference (P>0.05). The activity of the high-dose (160 mg / kg) was comparable to that of the positive drug fluoxetine (20 mg / kg), indicating that the compound has significant antidepressant activity.
[0250] Table 2 Results of the forced swimming test on compound 13 in mice
[0251]
[0252] Embodiment 30:
[0253] Formulation Examples
[0254] 1. Take any one or any combination of compounds 1-27, dissolve it with a small amount of DMSO, add injection water as usual, filter it, and sterilize it by filling to prepare an injection solution.
[0255] 2. Take any one or any combination of compounds 1-27, dissolve it with a small amount of DMSO, dissolve it in sterile water for injection, stir to dissolve, filter with a sterile suction funnel, filter aseptically, divide into ampoules, freeze-dry at low temperature, and aseptically seal to obtain powder injection.
[0256] 3. Take any one or any combination of compounds 1-27, add excipients at a weight ratio of 9:1 to the excipients, and prepare powders.
[0257] 4. Take any one or any combination of compounds 1-27, add excipients at a weight ratio of 5:1 to the excipients, and granulate and tablet.
[0258] 5. Take any one or any combination of compounds 1-27 and prepare an oral liquid according to a conventional oral liquid preparation method.
[0259] 6. Take any one or any combination of compounds 1-27, add excipients at a weight ratio of 5:1 to the excipients, and prepare capsules.
[0260] 7. Take any one or any combination of compounds 1-27, add excipients at a weight ratio of 3:1 to the excipients, and prepare capsules.
[0261] 8. Take any one or any combination of compounds 1-27, add excipients at a weight ratio of 5:1 to the excipients to prepare granules.
[0262] As can be seen from the above examples, the present invention provides a series of paeoveitol D derivatives, their preparation methods and applications, pharmaceutical compositions and applications. The paeoveitol D derivatives provided by the present invention have an effect on MT 1 and MT 2 The receptor has cytotoxic activity, can be combined with a pharmaceutically acceptable carrier or excipient to form a pharmaceutical composition, and can be used to treat or improve central nervous system diseases associated with melatonin receptors.
[0263] The above description is only a preferred embodiment of the present invention. It should be pointed out that a person skilled in the art can make several improvements without departing from the principle of the present invention, and these improvements should also be regarded as within the protection scope of the present invention.
Claims
1. Paeoveitol D derivatives 1, 4, 7-14, 16-23, 25-27 or pharmaceutically acceptable salts thereof represented by the following structural formula (I), 2. Use of the paeoveitol D derivatives 1, 4, 7-14, 16-23, 25-27 or pharmaceutically acceptable salts thereof represented by formula (I) according to claim 1 in the preparation of melatonin receptor agonists.
3. Use of the paeoveitol D derivatives 1, 4, 7-14, 16-23, 25-27 or pharmaceutically acceptable salts thereof of formula (I) as claimed in claim 1 in the preparation of drugs for treating or preventing central nervous system diseases.
4. Use of the paeoveitol D derivatives 1, 4, 7-14, 16-23, 25-27 or pharmaceutically acceptable salts thereof represented by formula (I) according to claim 1 in the preparation of drugs for central nervous system diseases related to melatonin receptors.
5. A method for preparing the paeoveitol D derivatives 1, 4, 7-14, 16-23, 25-27 of formula (I) as claimed in claim 1, It is characterized in that The method comprises the following steps: Preparation of compounds 1, 4, and 7: 5-methoxy-6-methylbenzofuran-3-carboxylic acid ethyl ester is reacted with a reducing agent to prepare compound 1; compound 1 and phthalimide are reacted with triphenylphosphine and an azo reagent to prepare compound 3 by Mitsunobu reaction; compound 3 is hydrolyzed with hydrazine hydrate to prepare compound 4; compound 1 is oxidized to prepare compound 7; the structural formula of compound 3 is: Preparation of compounds 8-14, 16-23, 25-27: Benzofuran-3-aldehyde compounds and primary or secondary amines are subjected to reductive amination in a suitable reaction solvent under the action of a suitable reducing agent to obtain compounds 8-14, 16, 17, 19-23, 25-27, wherein the benzofuran-3-aldehyde compounds include 6-methyl-5-methoxy-3-benzofuranaldehyde or 5-methoxy-3-benzofuranaldehyde or 5-methoxy-2-phenyl-3-benzofuranaldehyde, the suitable reaction solvent is dichloromethane or chloroform or methanol or ethanol, the suitable reducing agent is sodium borohydride or sodium triacetylborohydride or sodium cyanoborohydride, and compound 17 is subjected to removal of tert-butyloxycarbonyl under the action of a suitable acid to obtain compound 18, wherein the suitable acid is trifluoroacetic acid or p-toluenesulfonic acid.
6. A pharmaceutical composition comprising a therapeutically effective amount of any one or any combination of the paeoveitol D derivatives 1, 4, 7-14, 16-23, 25-27 of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
7. Use of the pharmaceutical composition according to claim 6 in the preparation of a melatonin receptor agonist.
8. Use of the pharmaceutical composition according to claim 6 in the preparation of a medicament for treating or preventing central nervous system diseases.
9. Use of the pharmaceutical composition according to claim 6 in the preparation of a drug for treating or preventing central nervous system diseases associated with melatonin receptors.
10. A method for preparing the pharmaceutical composition according to claim 6, It is characterized in that The method comprises the following steps: first preparing paeoveitol D derivatives 1, 4, 7-14, 16-23, 25-27, and then adding a pharmaceutically acceptable carrier, wherein the paeoveitol D derivatives 1, 4, 7-14, 16-23, 25-27 are prepared by the following steps: Preparation of compounds 1, 4, and 7: 5-methoxy-6-methylbenzofuran-3-carboxylic acid ethyl ester is reacted with a reducing agent to prepare compound 1; compound 1 and phthalimide are reacted with triphenylphosphine and an azo reagent to prepare compound 3 by Mitsunobu reaction; compound 3 is hydrolyzed with hydrazine hydrate to prepare compound 4; compound 1 is oxidized to prepare compound 7; the structural formula of compound 3 is: Preparation of compounds 8-14, 16-23, 25-27: Benzofuran-3-aldehyde compounds and primary or secondary amines are subjected to reductive amination in a suitable reaction solvent under the action of a suitable reducing agent to obtain compounds 8-14, 16, 17, 19-23, 25-27, wherein the benzofuran-3-aldehyde compounds include 6-methyl-5-methoxy-3-benzofuranaldehyde or 5-methoxy-3-benzofuranaldehyde or 5-methoxy-2-phenyl-3-benzofuranaldehyde, the suitable reaction solvent is dichloromethane or chloroform or methanol or ethanol, the suitable reducing agent is sodium borohydride or sodium triacetylborohydride or sodium cyanoborohydride, and compound 17 is subjected to removal of tert-butyloxycarbonyl under the action of a suitable acid to obtain compound 18, wherein the suitable acid is trifluoroacetic acid or p-toluenesulfonic acid.
